Status:
UNKNOWN
Influence of Aspirin on Human Gut Microbiota Composition and Metabolome
Lead Sponsor:
Chinese University of Hong Kong
Conditions:
Aspirin
Microbiota
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Colorectal cancer (CRC) is the third most common cancer type in males and the second in females, accounting for about 693,900 deaths worldwide per year. Although the annual CRC mortality rate is still...
Detailed Description
Colorectal cancer (CRC) is the third most common cancer type in males and the second in females, accounting for about 693,900 deaths worldwide per year. It is commonly accepted that aspirin exerts it...
Eligibility Criteria
Inclusion
- NSAID naïve during the last month;
- absence of drugs, nutrient supplements, probiotics, prebiotics and synbiotics that might interfere with microbial homeostasis for all participants;
- no past history of gastrointestinal bleeding or ulcers;
- absence of historical aspirin-induced side effects;
- voluntary and willing to cooperate during treatment; and
- consent with treatment and sample collection schedule
Exclusion
- unfit symptoms, such as epigastric pain, acid reflux, eructation and dyspepsia;
- diagnosis of any disease during the past 3 months;
- diarrhea within the previous 7 days;
- history of alcohol abuse, defined as \>80 g/d in men and \>40 g/d in women;
- pregnancy; and
- mental illness rendering the participants unable to understand the nature, scope, and possible consequences of the study
Key Trial Info
Start Date :
March 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03450317
Start Date
March 1 2018
End Date
December 31 2021
Last Update
August 1 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Prince of Wales Hospital
Hong Kong, Hong Kong, ba